证券代码：000919 证券简称：金陵药业 金陵药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------| | | | 编号：2023-002 | | | √特定对象调研 | □分析师会议 | | 投资者关系 | □媒体采访 □业绩说明会 | | | 活动类别 | □新闻发布会 □路演活动 | | | | □现场参观 □电话会议 | | | | □其他： （请文字说明其他活动内容） | | | | （排名不分先后） | | | | 兴业证券：徐尚微、姚晟瑜，中信保诚：陈爽， | | | 参与单位名称 | | 浦银安盛：徐博，兴银理财：卢新平，华安资产：房晓， ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥708,534,720.18, representing a 2.24% increase compared to ¥693,016,544.54 in the same period last year[5] - Net profit attributable to shareholders was ¥43,585,110.26, reflecting an 11.07% increase from ¥39,240,141.55 year-on-year[5] - Basic and diluted earnings per share increased by 12.48% to ¥0.0865 from ¥0.0769 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 708,534,720.18, an increase of 2.2% compared to CNY 693,016,544.54 in the same period last year[18] - Net profit for Q1 2023 reached CNY 49,325,374.22, representing a 10.5% increase from CNY 44,443,693.56 in Q1 2022[20] - The total comprehensive income attributable to minority shareholders for Q1 2023 was CNY 5,740,263.96, compared to CNY 5,203,552.01 in Q1 2022, representing an increase of approximately 10.3%[21] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.0865, up from CNY 0.0769 in Q1 2022, reflecting a growth of about 7.4%[21] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching -¥25,354,145.88, a 65.01% increase compared to -¥72,458,661.05 in the previous year[5] - Cash inflow from operating activities totaled CNY 675,761,687.56 in Q1 2023, compared to CNY 626,808,280.41 in Q1 2022, indicating an increase of approximately 7.8%[21] - Cash outflow from operating activities was CNY 701,115,833.44 in Q1 2023, slightly up from CNY 699,266,941.46 in Q1 2022, resulting in a net cash flow from operating activities of -CNY 25,354,145.88, an improvement from -CNY 72,458,661.05 in Q1 2022[21] - Investment activities generated a net cash flow of -CNY 209,375,029.15 in Q1 2023, compared to -CNY 460,424,469.27 in Q1 2022, showing a significant reduction in cash outflow[22] - Cash inflow from financing activities was CNY 3,681,573.36 in Q1 2023, down from CNY 23,616,000.00 in Q1 2022, indicating a decrease of approximately 84.4%[22] - The net increase in cash and cash equivalents for Q1 2023 was -CNY 231,087,932.62, compared to -CNY 524,349,156.37 in Q1 2022, reflecting an improvement in cash management[22] - The ending balance of cash and cash equivalents as of the end of Q1 2023 was CNY 1,243,795,533.31, compared to CNY 957,243,394.73 at the end of Q1 2022, representing an increase of approximately 30%[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,521,604,404.57, a slight decrease of 0.48% from ¥4,543,352,930.71 at the end of the previous year[5] - The total current assets decreased slightly to CNY 2,616,014,317.82 from CNY 2,633,145,031.76, reflecting a decline of 0.65%[15] - The total liabilities decreased to CNY 845,385,207.46 from CNY 916,299,000.51, indicating a reduction of approximately 7.7%[17] - The equity attributable to shareholders of the parent company increased to CNY 3,037,602,730.81 from CNY 2,994,177,727.86, reflecting a growth of 1.4%[17] Research and Development - The company reported a 49.55% increase in R&D expenses, totaling ¥14,231,193.78 compared to ¥9,516,114.99 in the previous year[9] - The company's R&D expenses increased to CNY 14,231,193.78, up from CNY 9,516,114.99, marking a 49.5% rise year-over-year[18] - The company has plans for market expansion and new product development, as indicated by ongoing investments in research and development[14] - The company’s financial performance indicates a stable outlook with a focus on cost management and strategic investments in R&D[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 50,056, with the largest shareholder holding 44.60% of the shares[10] Other Significant Events - Government subsidies recognized in the current period amounted to ¥8,458,972.91, a 407.63% increase from ¥1,666,372.01 in the previous year[9] - The company is in the process of issuing A-shares to specific investors, which may involve related transactions[14] - The company has received compensation for part of the demolition from Zhejiang Tianfeng Pharmaceutical Factory, which may impact future cash flows[13] - The company is adjusting its management structure, including changes to the board secretary, which may influence operational efficiency[14] - The company did not conduct an audit for the Q1 2023 report[23]

答：投资者，您好。关于福州市投资管理有限公司减持公司股份的情 况，请参阅《中国证券报》《证券时报》《上海证券报》及巨潮资讯网 刊登的《关于特定股东减持股份预披露公告》《特定股东减持股份计划 时间过半暨减持进展情况的公告》。谢谢！ 证券代码：000919 证券简称：金陵药业 金陵药业股份有限公司 金陵药业 2022 年度业绩说明会 投资者活动记录表 编号：2023-001 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □电话会议 □其他： （请文字说明其他活动内容） 参与单位名称 及人员姓名 金陵药业2022年度业绩说明会采用网络远程方式进行，面向全体投资 者 时间 2023 年 4 月 7 日 15:00-16:30 地点 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈"栏目 公司接待人员 姓名 主持人：金陵药业 董事长：梁玉堂 副董事长、总裁：陈亚军 董秘：陈海 副总裁、总会计师：汪洋 独立董事：沈永建 投资者关系活动 主要内容介绍 1.陈总裁好，我想问下公司 2022 年控股的池州东升药业进展怎样？ ...

易"平台（http://irm.cninfo.com.cn/）或下方二维码留言提问， 公司将对投资者普遍关注的问题进行回答。欢迎广大投资者积极参与。 金陵药业股份有限公司 关于召开 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 金陵药业股份有限公司（以下简称"公司"）已于 2023 年 3 月 24 日在巨潮资讯网（www.cninfo.com.cn）披露了《公司 2022 年年 度报告》（公告编号：2023-031）。 为使广大投资者进一步了解公司 2022 年年度报告的相关内容， 公司定于 2023 年 4 月 7 日（星期五）下午 3:00-4:30 举行 2022 年度 网上业绩说明会，本次年度业绩说明会将通过深圳证券交易所提供的 "互动易"平台举行，投资者可登录"互动易"平台 （http://irm.cninfo.com.cn）,进入"云访谈"栏目参与本次年度 业绩说明会。 出席本次年度业绩说明会的人员有：董事长梁玉堂先生，副董事 长、总裁陈亚军先生，独立董事沈永建先生，副总裁、总会计师汪洋 先生和董事会秘书陈海 ...

Financial Performance - The company's operating revenue for 2022 was approximately ¥2.67 billion, a decrease of 4.91% compared to ¥2.81 billion in 2021[24]. - The net profit attributable to shareholders for 2022 was approximately ¥105.28 million, down 12.72% from ¥120.63 million in 2021[24]. - The net profit after deducting non-recurring gains and losses was approximately ¥63.72 million, a decline of 11.70% from ¥72.16 million in 2021[24]. - The cash flow from operating activities for 2022 was approximately ¥260.59 million, a decrease of 10.76% compared to ¥292.03 million in 2021[24]. - The total assets at the end of 2022 were approximately ¥4.54 billion, an increase of 2.15% from ¥4.45 billion at the end of 2021[24]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥2.99 billion, up 2.27% from ¥2.93 billion at the end of 2021[24]. - The basic earnings per share for 2022 were ¥0.2089, down 12.70% from ¥0.2393 in 2021[24]. - The weighted average return on equity for 2022 was 3.54%, a decrease of 0.62% from 4.16% in 2021[24]. - The company achieved total operating revenue of 2,670.968 million yuan and a net profit attributable to shareholders of 1,052.819 million yuan in 2022[48]. - The company reported a gross margin of 34.37% for pharmaceutical production and sales, which is an increase of 1.47% compared to the previous year[59]. - The company reported a total revenue of 1,273,108,500 CNY for its subsidiary Suqian Hospital, with a net profit of 32,964,877 CNY[88]. - The company reported a total revenue of 2.8836 billion CNY for the year 2022, reflecting a significant growth compared to the previous year[106]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2022, representing a year-over-year increase of 10%[114]. Dividend Distribution - The company plans to distribute a cash dividend of 1.0 RMB per 10 shares (including tax) based on a total of 511,136,000 shares[3]. - The cash dividend distribution plan for the reporting period included a cash dividend of 1.0 yuan per 10 shares, totaling 51,113,600 yuan, which represents 100% of the total profit distribution[138]. - The company has maintained a complete decision-making process for its cash dividend policy, ensuring the protection of minority shareholders' rights[138]. - The company plans to distribute a cash dividend of CNY 1.00 per 10 shares, totaling CNY 51,113,600.00, with the remaining undistributed profit of CNY 811,804,540.03 carried forward to future years[140]. Business Operations and Strategy - The company has expanded its business scope to include medical services and health care services following acquisitions in 2003 and 2018[22]. - The company’s business model remains unchanged compared to the previous year, focusing on pharmaceutical manufacturing and healthcare services[44]. - The company is focusing on expanding its market presence through diversified product sales, including medical devices and agricultural products[49]. - The company is committed to enhancing its operational efficiency by dynamically adjusting production plans and improving resource allocation[49]. - The company is focusing on expanding its market presence and enhancing its product offerings through new technology development and strategic acquisitions[110]. - The company is strategically positioned to leverage its experienced management team to drive future growth and operational efficiency[110]. - The company plans to pursue strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential mergers in 2023[114]. Research and Development - The company invested CNY 74.17 million in R&D during the reporting period, representing a year-on-year increase of 30%[52]. - Research and development expenses increased by 30.09% to CNY 74,170,064.98, driven by new projects[67][68]. - The company has a total of 13 employees with doctoral degrees and 388 with master's degrees, reflecting a strong educational background among its workforce[134]. - The company has established a dedicated committee for innovation development, aiming to enhance its competitive edge in the market[112]. - The company’s new product "Cicada Slough Cough Granules" has completed clinical research and is awaiting approval[54]. - The company has been actively involved in various technology projects, including the successful application for the Jiangsu Province Science and Technology Achievement Transformation Project[52]. Market and Competition - The company acknowledges risks related to industry policy changes, market competition, and raw material price fluctuations[3]. - The company aims to enhance its product quality and R&D capabilities to maintain competitive advantages in a highly concentrated market[91]. - The company is focusing on expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[114]. Governance and Compliance - The company has implemented a governance structure that complies with relevant laws and regulations, enhancing its governance level[96]. - The board of directors operates independently, with specialized committees focusing on strategy, audit, nomination, and remuneration[97]. - The company emphasizes transparent information disclosure, utilizing multiple media outlets to ensure all investors have equal access to information[98]. - The company has established an independent financial department with a standardized accounting system and independent bank accounts, ensuring compliance with tax regulations[100]. - The company has implemented a comprehensive internal control system to ensure compliance with relevant laws and regulations[148]. - The internal control audit report issued on March 24, 2023, received a standard unqualified opinion, confirming the effectiveness of financial reporting controls[153]. Environmental Management - The company has implemented self-monitoring plans in accordance with relevant regulations, ensuring stable compliance with pollutant discharge[164]. - The company invested CNY 9.2799 million in environmental protection efforts[168]. - The company maintained compliance with environmental regulations, adhering to standards set by various environmental protection laws[156]. - Jinling Pharmaceutical's environmental management practices include strict adherence to wastewater and air quality standards, demonstrating commitment to sustainability[156]. Employee Management - The total number of employees at the end of the reporting period was 4,880, with 3,475 in technical roles, 458 in production, and 95 in sales[134]. - The company conducted 481 training programs in 2022, achieving an overall training plan completion rate of over 85% and spending over 3 million yuan on education expenses[136]. - The company has implemented a flexible benefits plan to meet diverse employee welfare needs and enhance employee satisfaction[135]. - The company has established a dual-driven talent development system focusing on theoretical learning and practical training[135]. Legal and Regulatory Matters - The company has not reported any significant changes in its business, products, or services during the reporting period[66]. - There were no significant lawsuits or arbitration matters during the reporting period[188]. - The company reported no violations of external guarantees during the reporting period[181]. - The company did not experience any bankruptcy reorganization during the reporting period[187].

证券代码：000919 证券简称：金陵药业 金陵药业股份有限公司投资者关系活动记录表 | --- | --- | |----------------------------|----------------------------------------------------------------| | 投资者关系活动类别 | 金陵药业机构投资者调研交流会 | | | 华泰证券、华创证券、银河证券、东方证券、光大证券、工银瑞 | | 参与单位名称及人员姓名 | 信、华夏基金、长信基金、南方基金、交银施罗德、招商基金、兴业基 | | | 金、鹏华基金、天弘基金、华鑫基金等机构投资者 | | 日 期 | 2014 年 11 月 4 日 | | 地 点 | 本公司会议室 | | 上市公司接待人员姓名 | 公司董事会秘书 徐俊扬 先生 | | 投资者关系活动主要内容介绍 | 详见附件 | | | 接待过程中，公司接待人员与投资者进行了交流与沟通，严 | | 相关说明 | 格按照有关制度规定，没有出现未公开重大信息泄露等情况。 | | | | 附件：投资者关系活动主要内容介绍 问：请问一下公司今后的医疗服务布局以及 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥701,676,933.27, representing a year-on-year increase of 1.87%[5]. - Net profit attributable to shareholders for the same period was ¥33,735,225.06, a significant increase of 56.47% compared to the previous year[5]. - The basic earnings per share for Q3 2022 was ¥0.0661, up by 54.47% year-on-year[5]. - Total operating revenue for the current period is ¥2,053,856,118.01, a decrease of 2.7% from ¥2,111,013,131.98 in the previous period[23]. - Net profit for the current period is ¥105,406,239.67, a decrease of 14.0% compared to ¥122,756,762.52 in the previous period[24]. - Basic and diluted earnings per share for the current period are both ¥0.1826, down from ¥0.1935 in the previous period[25]. - Total comprehensive income for the current period is ¥119,568,574.16, slightly down from ¥122,756,762.52 in the previous period[25]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,558,330,945.72, reflecting a 2.49% increase from the end of the previous year[5]. - As of September 30, 2022, the total assets of Jinling Pharmaceutical Co., Ltd. amounted to CNY 4,558,330,945.72, an increase from CNY 4,447,665,260.23 at the beginning of the year[21]. - The company's current assets totaled CNY 2,395,433,878.20, compared to CNY 2,288,834,000.04 at the start of the year, reflecting a growth of approximately 4.65%[20]. - The total liabilities stood at CNY 909,166,026.93, slightly down from CNY 913,096,006.32 at the beginning of the year[21]. - The equity attributable to shareholders of the parent company increased to CNY 3,007,413,799.43 from CNY 2,927,728,885.61, marking an increase of about 2.72%[21]. Cash Flow - The company's cash flow from operating activities decreased by 32.74% year-on-year, totaling ¥141,229,553.92[5][13]. - The net cash flow from operating activities for Q3 2022 was ¥141,229,553.92, a decrease of 32.8% compared to ¥209,965,324.74 in Q3 2021[27]. - The total cash and cash equivalents at the end of Q3 2022 stood at ¥1,122,269,631.54, an increase from ¥1,020,710,012.97 in Q3 2021[27]. - The company reported a total cash outflow from operating activities of ¥1,925,915,764.21, which is an increase from ¥1,879,745,650.11 in Q3 2021[27]. - Cash inflow from financing activities totaled ¥29,272,880.00, up from ¥15,000,000.00 in Q3 2021[27]. - The net cash flow from financing activities was -¥46,078,805.56, compared to -¥38,031,678.88 in the previous year[27]. Expenses and Income - The company's goodwill increased by 72.59% due to the acquisition of a 65.00% stake in Chizhou Dongsheng Pharmaceutical Co., Ltd.[9]. - Non-operating income for the year increased by 147.86% due to higher government subsidies received[11]. - Investment income decreased by 54.02% year-on-year, primarily due to the absence of performance compensation from subsidiaries[12]. - The company reported a 36.00% decrease in income tax expenses compared to the previous year, attributed to a reduction in taxable income[13]. - Research and development expenses increased to ¥45,168,326.22, up 14.5% from ¥39,351,727.41 in the previous period[24]. - Cash received from sales of goods and services is ¥2,041,251,922.89, a decrease of 1.0% from ¥2,061,084,625.63 in the previous period[26]. - Other income for the current period is ¥7,781,011.80, an increase from ¥3,139,232.80 in the previous period[24]. - Investment income for the current period is ¥10,752,550.99, down from ¥23,385,821.36 in the previous period[24]. Inventory and Receivables - Accounts receivable increased to CNY 409,019,830.84 from CNY 320,639,675.01, representing a rise of about 27.5%[20]. - The company reported a decrease in inventory to CNY 226,891,654.63 from CNY 245,476,356.41, a reduction of approximately 7.5%[20]. Other Information - The company has not reported any new product launches or technological advancements in this quarter[20]. - There are no significant updates regarding market expansion or mergers and acquisitions mentioned in the report[20]. - The company continues to utilize idle funds for wealth management products, as indicated in previous announcements[17].

Share Capital and Dividends - Jinling Pharmaceutical's total shares increased from 504 million to 510.4 million after the completion of the restricted stock incentive plan in February 2022[22]. - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[4]. - The company has not distributed cash dividends or bonus shares for the half-year period[78]. - The company completed the grant registration of 6.4 million restricted stocks to 72 incentive objects at a grant price of 3.69 CNY per share[82]. - The company received approval from the Nanjing State-owned Assets Supervision and Administration Commission for its 2021 restricted stock incentive plan[81]. - The company issued 6.4 million A-shares at a price of 3.69 RMB per share on January 17, 2022, with the shares listed on February 16, 2022[130]. - A total of 72 incentive recipients were granted 6.4 million restricted shares under the 2021 Restricted Stock Incentive Plan, with the grant date set on January 27, 2022[132]. Financial Performance - The company's total revenue for the reporting period was CNY 1,352,179,184.74, a decrease of 4.92% compared to the same period last year[23]. - Net profit attributable to shareholders was CNY 59,211,354.27, down 22.05% year-over-year[23]. - The net cash flow from operating activities was CNY 413,347.66, a significant decline of 99.75% compared to the previous year[23]. - Basic and diluted earnings per share were both CNY 0.1165, reflecting a decrease of 22.69% from the prior year[23]. - The company's total operating revenue for the reporting period was ¥1,352,179,184.74, representing a decrease of 4.92% compared to ¥1,422,221,213.81 in the same period last year[46]. - The total profit for the first half of 2022 was CNY 83,347,790.98, a decline of 31.4% from CNY 121,495,799.91 in the previous year[156]. - The company reported a net profit margin of approximately 6.5% for the first half of 2022, down from 8.9% in the same period of 2021[155]. - The company achieved a net profit of CNY 68,180,188.34, a decrease of 27.5% compared to CNY 93,889,092.81 in the first half of 2021[156]. Assets and Liabilities - The company's total assets increased by 1.27% to CNY 4,503,977,145.82 compared to the end of the previous year[23]. - The net assets attributable to shareholders rose by 1.57% to CNY 2,973,678,574.37[23]. - Cash and cash equivalents decreased to ¥1,078,057,736.57, accounting for 23.94% of total assets, down 9.83% from the previous year due to subsidiary investments[52]. - Accounts receivable increased to ¥387,359,636.38, representing 8.60% of total assets, up 1.39% from the previous year[52]. - Total liabilities decreased to CNY 887,027,567.38 from CNY 913,096,006.32, indicating a reduction of about 2.9%[150]. - The total assets at the end of the reporting period amounted to 510.4 million yuan, with total liabilities of 483.4 million yuan[176]. Research and Development - The company invested CNY 20.0975 million in research and development during the reporting period[41]. - Research and development expenses amounted to ¥20,097,465.06, down 11.49% from ¥22,707,636.56 in the previous year[46]. - The company is cautious about R&D risks associated with new drug development and is optimizing its R&D strategy[73]. - The R&D expenses for the period were 380 million, accounting for approximately 11.6% of total revenue[168]. - Research and development expenses for the first half of 2022 were 2.9 million yuan, which is a 4.3% increase from the previous year[169]. Market Position and Strategy - The company maintained its focus on pharmaceutical manufacturing and healthcare services, with key products including Suplife and Pilex[32][33]. - The company is positioned in a strategic industry that is crucial for national health and economic development, with a strong reputation in the pharmaceutical sector[35]. - The company plans to focus on expanding its market presence and investing in new product development in the upcoming quarters[155]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2023[167]. - The company is exploring potential acquisitions to enhance its product portfolio and market position[167]. Risk Management - The report emphasizes the importance of risk awareness regarding industry policy changes and market competition risks[3]. - The company is committed to risk management, implementing a dual prevention mechanism for risk control[39]. - The company is facing risks from industry policy changes, including drug approval and price control measures, and plans to adapt its business model accordingly[70]. Environmental and Social Responsibility - The company is focusing on improving its environmental management systems to comply with stricter regulations in the pharmaceutical industry[72]. - The company has implemented two wastewater treatment facilities with capacities of 1200 m³/d and 800 m³/d, ensuring that treated wastewater meets discharge standards[85]. - The company’s environmental monitoring results indicate that all pollutants are discharged within the standards[88]. - The company organized 178 personnel to assist in COVID-19 testing, completing 1.1 million tests across various cities[38]. - The company actively supports rural revitalization projects, achieving sales revenue of 330,000 CNY and a profit of 130,000 CNY from the honeysuckle tea project from January to June 2022[92]. Corporate Governance - The financial report is guaranteed to be true, accurate, and complete by the company's management, including the chairman and accounting heads[3]. - The report indicates that all board members attended the meeting to review the report, ensuring collective responsibility for its contents[3]. - The company has revised its articles of association and related governance rules as part of its corporate governance improvements[119]. - The company follows the accounting standards set by the Ministry of Finance, ensuring that its financial statements reflect its financial position accurately[193]. Legal and Compliance - The company is currently involved in a lawsuit seeking 1,772.32 million RMB related to a share transfer dispute, which is still under review[102]. - The company has not reported any major litigation or arbitration matters during the reporting period[102]. - There are no violations regarding external guarantees reported during the period[99]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[90].

Financial Performance - The company's operating revenue for Q1 2022 was ¥693,016,544.54, a decrease of 1.22% compared to ¥701,603,298.78 in the same period last year[3] - Net profit attributable to shareholders increased by 12.12% to ¥39,240,141.55 from ¥34,999,569.83 year-on-year[3] - Net profit for the current period is ¥44,443,693.56, an increase of 4.4% compared to ¥42,567,636.65 in the previous period[21] - Operating profit for the current period is ¥54,849,544.06, slightly down from ¥56,428,216.74, a decrease of 2.8%[21] - Basic earnings per share increased to ¥0.0769 from ¥0.0694, reflecting a growth of 7.2%[22] Cash Flow - The net cash flow from operating activities decreased significantly by 451.37%, resulting in a negative cash flow of ¥72,458,661.05 compared to a positive cash flow of ¥20,621,729.67 in the previous year[3] - Cash flow from operating activities shows a net outflow of ¥72,458,661.05, compared to a net inflow of ¥20,621,729.67 in the previous period[25] - Cash flow from investment activities resulted in a net outflow of ¥460,424,469.27, worsening from a net outflow of ¥269,446,173.11 in the previous period[25] - The net cash flow from financing activities was 8,534,333.34, compared to a negative cash flow of -67,000.00 in the previous year[26] - The total cash inflow from financing activities was ¥23,616,000.00, with no previous inflow recorded[25] - The total cash and cash equivalents at the end of the period decreased to 957,243,394.73 from 1,049,446,008.63 year-over-year[26] - The net increase in cash and cash equivalents was -524,349,156.37, compared to -248,891,096.60 in the same period last year[26] - The cash flow out from financing activities totaled 15,081,666.66, compared to 67,000.00 in the previous year[26] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,440,343,153.87, a slight decrease of 0.16% from the previous year-end[3] - The company's cash and cash equivalents decreased to RMB 976,861,077.66 from RMB 1,501,760,713.59, representing a decline of approximately 34.8%[16] - Accounts receivable increased to RMB 410,485,224.32 from RMB 320,639,675.01, reflecting a growth of about 28.0%[16] - The company's inventory stood at RMB 246,328,627.03, showing a marginal increase from RMB 245,476,356.41[16] - Total liabilities decreased to RMB 837,714,206.40 from RMB 913,096,006.32, indicating a reduction of approximately 8.2%[19] - The equity attributable to shareholders of the parent company increased to RMB 2,990,585,027.16 from RMB 2,927,728,885.61, marking an increase of about 2.1%[19] Investments and Expenses - Research and development expenses rose by 37.13% compared to the same period last year, indicating increased investment in innovation[8] - Research and development expenses increased to ¥9,516,114.99, up 37% from ¥6,939,640.95 in the previous period[21] - The company's investment income decreased by 83.63% year-on-year, attributed to reduced gains from long-term equity investments[9] - The company's prepayments increased by 136.84% compared to the beginning of the year, reflecting a rise in procurement activities[7] - The company's intangible assets increased by 81.21% compared to the beginning of the year, mainly due to the acquisition of land use rights[7] - The company completed the registration of its 2021 restricted stock incentive plan, increasing its registered capital by RMB 6,400,000 to RMB 510,400,000[13] - Jinling Pharmaceutical's subsidiary acquired land use rights for a plot in Hefei, indicating ongoing expansion efforts[13] - The company successfully completed the acquisition of a stake in Chizhou Dongsheng Pharmaceutical Co., Ltd., enhancing its investment portfolio[13] - The company's intangible assets rose significantly to RMB 254,047,202.33 from RMB 140,196,138.05, reflecting an increase of approximately 81.0%[18] Other Information - The company's weighted average return on equity increased to 1.33% from 1.22% year-on-year[3] - The first quarter report was not audited[27] - The company did not pay dividends or profits to minority shareholders during the first quarter[26]

Financial Performance - The company's operating revenue for 2021 was ¥2,808,754,876.16, representing a 12.18% increase compared to ¥2,503,732,374.15 in 2020[21]. - The net profit attributable to shareholders for 2021 was ¥120,625,946.04, an increase of 85.19% from ¥65,136,495.93 in 2020[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 15.53% to ¥72,159,809.38 in 2021 from ¥85,427,396.25 in 2020[21]. - The basic earnings per share for 2021 was ¥0.2393, up 85.22% from ¥0.1292 in 2020[21]. - The total assets at the end of 2021 were ¥4,447,665,260.23, a 3.83% increase from ¥4,283,570,372.62 at the end of 2020[22]. - The net assets attributable to shareholders at the end of 2021 were ¥2,927,728,885.61, reflecting a 2.46% increase from ¥2,857,463,167.29 at the end of 2020[22]. - The net cash flow from operating activities for 2021 was ¥292,026,282.03, a decrease of 6.24% from ¥311,464,432.11 in 2020[21]. - The company reported non-recurring gains of ¥53,131,553.79 from the disposal of non-current assets in 2021, compared to a loss of ¥1,581,888.97 in 2020[26]. - The weighted average return on equity for 2021 was 4.16%, an increase of 1.90% from 2.26% in 2020[21]. Dividend Policy - The company plans to distribute a cash dividend of 1.00 RMB per 10 shares (including tax) based on a total share capital of 510,400,000 as of March 25, 2022[6]. - The total amount of cash dividends distributed accounted for 100% of the available profits for distribution[144]. - The cash dividend per 10 shares is CNY 1.00 (including tax), based on a total share capital of 510,400,000 shares[144]. - The company maintained a complete decision-making process for its cash dividend policy, ensuring the rights of minority shareholders were protected[144]. Risks and Challenges - The company acknowledges risks including industry policy changes, operational risks due to the COVID-19 pandemic, and market competition risks[6]. - The company faces risks from industry policy changes, including drug approval and price control measures, which may impact future growth[92]. - The company is addressing the risk of raw material price fluctuations by optimizing procurement processes and maintaining reserves of commonly used raw materials[93]. - The company is committed to improving research and development capabilities to mitigate risks associated with new drug development and market acceptance[94]. Market and Industry Insights - The pharmaceutical industry in China is projected to grow significantly, driven by increased healthcare awareness and rising demand for medications, with total healthcare expenditure expected to reach CNY 7.23 trillion in 2020[1]. - The healthcare market in China is expected to maintain rapid growth due to economic development, population growth, and increasing health awareness among residents[3]. - The aging population in China is substantial, with 264.02 million individuals aged 60 and above, representing 18.7% of the total population, indicating a growing market for healthcare services[2]. - In 2021, the total number of medical visits in China reached 6.05 billion, a year-on-year increase of 22.4%, with public hospitals accounting for 3.22 billion visits, up 28.3%[3]. Corporate Governance - The company’s financial report is guaranteed to be true, accurate, and complete by the board of directors and senior management[5]. - The company has established a strong governance structure with independent directors to ensure compliance and strategic oversight[112][115]. - The company maintains independent operations from its controlling shareholder, ensuring no infringement on the rights of other shareholders[100]. - The company has a clear governance structure that operates independently from its controlling shareholder, ensuring no hierarchical relationship exists[103]. Research and Development - The company invested CNY 57.0147 million in research and development during the reporting period[50]. - The company holds 14 patent applications, including 3 invention patents and 11 utility model patents, with 18 patents granted[50]. - The company is actively pursuing new product development and has made progress in secondary development of existing products, including obtaining a patent for a detection method[50]. - The company has filed 103 research projects, with 20 approved, including 6 at the national level[50]. Social Responsibility - The company participated in 30 public welfare volunteer activities in 2021, investing a total of RMB 1.58 million, including RMB 1.4 million for pandemic relief efforts[162]. - In 2021, the company allocated RMB 180,000 for poverty alleviation initiatives, including RMB 120,000 for healthcare support and RMB 42,000 for educational assistance to 99 impoverished students[164]. - The company has committed to corporate social responsibility by integrating public welfare support into its annual budget[163]. - The company has actively engaged in industry poverty alleviation projects, including donations for community health and education initiatives[164]. Environmental Compliance - The company has implemented wastewater treatment facilities with capacities of 1200m³/d and 800m³/d, ensuring compliance with environmental standards[157]. - The company achieved a total COD discharge of 26.38 tons, which is below the regulatory limits, demonstrating effective pollution control measures[157]. - The company maintains a pollution discharge permit, with all emissions compliant with the permit requirements[158]. - The company conducted an environmental self-monitoring program, confirming that all pollutant emissions met standards during the reporting period[160]. Employee and Management - The total number of employees at the end of the reporting period was 4,865, with 906 in the parent company and 3,959 in major subsidiaries[138]. - The company had 3,430 technical personnel, representing approximately 70.5% of the total workforce[138]. - The training budget for 2021 was set at 5.8535 million yuan, with over 80% of the annual training plan achieved[141]. - The company implemented a competitive salary policy to enhance employee motivation and has established a dual career development channel[140]. Future Outlook - In 2022, the company plans to focus on strengthening technological innovation and enhancing the transformation of innovative achievements[91]. - The company aims to accelerate digital transformation to cultivate new growth drivers for development[91]. - Future guidance indicates a cautious optimism for revenue growth, contingent on market conditions and successful product development[110]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence[121].